Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has received approval from the U.S. Food and Drug Administration for its new rapid-acting insulin, marketed as Lyumjev.
The company says the injectable medication helps to improve glycemic control in adults with type 1 and type 2 diabetes.
Lilly said the insulin, when delivered during mealtime, helps control high blood sugar levels after eating. The novel formulation speeds-up absorption into the bloodstream and reduce A1C levels.
“With its fast onset, Lyumjev is a meaningful development for people who want their insulin to help manage their A1C and reduce those post-meal spikes,” said Mark Warren, M.D., assistant professor of medicine, Campbell University of Osteopathic Medicine.
The company said Lyumjev demonstrated “superior reduction” in blood glucose spikes at both one hour and two hours after a test meal compared to Humalog, another insulin medication made by Lilly.
The treatment is not yet available on the market. When it does, Lilly said Lyumjev will be included in the Lilly Insulin Value Program, which allows anyone with commercial insurance and those without insurance to fill their monthly prescription for $35.